Physician profile
Tajammul Ehsan
NPI 1760583397
$12,265.06
in general payments reported to CMS, 2019-2025
51 companies · $2,553 in 2025
The $2,553 reported for 2025 was more than what 76% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,072 · 2020: $778 · 2021: $637 · 2022: $1,254 · 2023: $1,971 · 2024: $2,000 · 2025: $2,553.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,510 · Education: $13.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,510.24 |
| Education | $13.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,150.40 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $1,028.74 | 2019-2025 | |
| Genzyme Corporation | $917.89 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $756.52 | 2019-2024 | Ajovy |
| Lilly USA, LLC | $727.97 | 2019-2025 | Kisunla, Amyvid |
| Genentech USA, INC. | $713.77 | 2019-2025 | Ocrevus, Ocrevus Zunovo, Enspryng |
| Ucb, INC. | $671.16 | 2019-2025 | Nayzilam, Briviact |
| Biogen, INC. | $635.72 | 2019-2025 | Tysabri, Vumerity, Leqembi |
| Amneal Pharmaceuticals LLC | $510.99 | 2023-2025 | Crexont, Rytary |
| Otsuka America Pharmaceutical, INC. | $416.34 | 2023-2025 | Rexulti, Nuedexta |
| Emd Serono, INC. | $413.43 | 2019-2025 | Mavenclad, Mavenclad |
| Neurelis, INC. | $385.46 | 2021-2025 | Valtoco |
| Amgen INC. | $357.25 | 2019-2022 | |
| Eisai INC. | $293.12 | 2019-2025 | |
| Jazz Pharmaceuticals INC. | $281.89 | 2021-2024 |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tajammul Ehsan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.